Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance

Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial

The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival

Pfizer and FITT IIT Delhi identify 20 health startups under innovation programme

Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations

Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India

Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial

Glenmark posts strong FY26 results with 27.5% revenue jump

Lupin wins FDA nod for generic colonoscopy prep drug with first-to-file exclusivity

Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term